Drug
Patritumab Deruxtecan
Patritumab Deruxtecan: highest development phase Phase 3, developed by Daiichi Sankyo, Merck. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Daiichi Sankyo, Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Patritumab deruxtecan NCT07060807 | Phase 3 | Breast Neoplasms |
| Patritumab Deruxtecan (Fixed dose) NCT04619004 | Phase 2 | Non-Small Cell Lung Cancer Metastatic |
| Patritumab deruxtecan NCT06797635 | Phase 2 | Breast Neoplasms |
| Patritumab Deruxtecan NCT06941272 | Phase 1/2 | Malignant Neoplasm |
| Patritumab deruxtecan NCT06686394 | Phase 1/2 | Breast Neoplasms |
Latest
No recent events.
Follow Patritumab Deruxtecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.